Findings from the Phase III EINSTEIN-DVT study with Rivaroxaban have been presented during the Hot Line Session at the Annual Meeting of the European Society of Cardiology (ESC) in Stockholm, Sweden on August 31, 2010, 11:00-12:30 CEST. On this occasion we have held a conference call for investors and analysts.
Ad-hoc-Announcement from August 4, 2010 |
On-demand audio recording of the Q2 2010 Investor Conference Call
PDF / 270 KB 
collectQ2_2010_ConferenceCall_2010-07-29_Redecharts.pdf Q2 2010 Investor Conference Call Presentation Chartspdf
Financial Report as of June 30, 2010 PDF / 1.73 MB collectQB_2010_2_e.pdf Financial Report as of June 30, 2010pdf
Q2 2010 Analyst and Investor Briefing PDF / 268 KB collectBayer_Q2_2010_Analyst_and_Investor_Briefing.pdf Q2 2010 Analyst and Investor Briefingpdf
